Amoxicillin (a-amino-p-hydroxybenzyl penicillin, BRL 2333) is a new semisynthetic penicillin which is structurally similar to ampicillin, but which is better absorbed and yields higher concentrations in serum and urine. The in vitro susceptibility of 145 strains of Enterobacteriaceae and 30 isolates of Pseudomons aeruginosa was determined against various concentrations of amoxicillin and ampicillin in agar. In addition, inhibitory zones around discs containing 10 pg of amoxicillin were measured and compared with results of agar dilution studies. The drug also was evaluated in the treatment of 38 patients with bacteriuria, who received doses of either 750 mg or 1 g/day for 10 days. In vitro, amoxicillin was comparable in activity to ampicillin; most isolates of Eswherichia coli and Proteus mirabili8 were inhibited by 10 pg or less/ml, whereas the majority of strains of Enterobacter, Klebsiella, indole-positive Proteus species, and Psudomonas grew in concentrations greater than 50 ,sg/ml. Clinically, amoxicillin was effective in eradicating bacteriuria due to susceptible organisms and was very well tolerated. For practical purposes, however, amoxicillin performed no better than a host of other drugs presently available for the treatment of acute, uncomplicated bacteriuria.
Amoxicillin (a-amino-p-hydroxybenzyl penicillin, BRL 2333) is a new penicillin structurally similar to ampicillin, differing only in the hydroxylation of the phenyl side chain (Fig. 1) . Results of previous studies indicated that amoxicillin has an antibacterial spectrum comparable to that of ampicillin (6, 10) , but that it is better absorbed after oral administration and thus provides higher concentrations in serum (4, 7) . In addition, the excretion of amoxicillin in the urine has been correspondingly greater than that of ampicillin (7) . The present report describes further the in vitro activity of amoxicillin and also its effect in the treatment of 38 patients with inifections of the urinary tract. MATERIALS Prior to therapy with amoxicillin, 36 of the 38 patients had organisms which were susceptible in vitro to 10,jg or less of amoxicillin per ml. All of the patients were women; their ages ranged from 18 to 73 years. Only six of the total group of patients had azotemia or structural abnornalities of the urinary tract. The patients were treated with 250 mg of amoxicillin three or four times a day for 10 days. The criteria employed for selection of patients with urinary tract infections, collection and quantitation of bacteriological specimens, and performance of serological typing have been described in previous publications (5, 8) .
A survey for possible hematological, renal, and hepatic toxicity was made by determination of the hematocrit, total and differential white blood cell counts, urinalysis, blood urea nitrogen, alkaline phosphatase, and serum glutamic oxalacetic transaminase at the onset, during, and after treatment with amoxicillin in most patients. RESULTS In vitro susceptibility of gram-negative pathogens to amoxicillin and ampicillin.
The antibacterial activity of amoxicillin and ampicillin against approximately 30 isolates each of Escherichia coli, Proteus mirabilis, Kiebsiella, Enterobacter, and indole-positive Proteus species is depicted in Fig. 2-4 , which also show the effect of inoculum size on determination of the MIC. At a concentration of 10 jg or less/ml, amoxicillin or ampicillin inhibited 89% of the strainis of E. coli. Similarly, all 30 isolates of P. mirabilis were inhibited by 5 ug or less of either drug per ml. On the other hand ( Fig. 3 and 4 
DISCUSSION
It is apparent that amoxicillin has an antibacterial spectrum identical to that of ampicillin. The sole advantage of amoxicillin is that it produces consistently higher levels of antibiotic in blood and urine than do comparable doses of ampicillin, a result probably related to better gastrointestinal absorption. Although in the present study amoxicillin was effective in eradicating bacteriuria due to susceptibile organisms and was very well tolerated, the outcome of infection was most clearly related to the diagnostic category of urinary tract infection. For example, persistence or recurrence of bacteriuria after cessation of treatment was more common in patieints with a previous history of infectioil or with associated structural and functional abnormalities of the urinary tract. For practical purposes, amoxicillin performed no better than a host of other drugs presently available for the treatment of acute, uncomplicated bacteriuria. Although amoxicillin has been demonstrated to be better than ampicillin in the treatment of experimental infections in animals (1), whether or not amoxicillin will be any more effective clinically remains to be seen. A possible role for amoxicillin will be in the treatment of gonococcal urethritis. Preliminary results from our laboratory have demonstrated that a single dose of 3.0 g of amoxicillin may have activity superior to that of other agents which can be administered by mouth.
